YL-15293

· Shanghai YingLi Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for YL-15293, covering 2021-11-15 to 2023-07-18. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation [Phase 1, Phase 2]